USS Investment Management Ltd Grows Stock Position in Eli Lilly and Company $LLY

USS Investment Management Ltd lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 141,359 shares of the company’s stock after buying an additional 4,003 shares during the period. USS Investment Management Ltd’s holdings in Eli Lilly and Company were worth $130,067,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. IFM Investors Pty Ltd grew its position in Eli Lilly and Company by 3.4% during the first quarter. IFM Investors Pty Ltd now owns 164,685 shares of the company’s stock valued at $151,472,000 after buying an additional 5,446 shares during the period. Rexford Capital Inc. increased its holdings in Eli Lilly and Company by 4.3% during the first quarter. Rexford Capital Inc. now owns 1,656 shares of the company’s stock valued at $1,523,000 after buying an additional 68 shares during the last quarter. Severin Investments LLC raised its position in Eli Lilly and Company by 25.9% in the first quarter. Severin Investments LLC now owns 884 shares of the company’s stock worth $813,000 after acquiring an additional 182 shares during the period. Walker Asset Management LLC raised its position in Eli Lilly and Company by 1.8% in the first quarter. Walker Asset Management LLC now owns 670 shares of the company’s stock worth $617,000 after acquiring an additional 12 shares during the period. Finally, North Point Portfolio Managers Corp OH boosted its stake in shares of Eli Lilly and Company by 11.2% during the 1st quarter. North Point Portfolio Managers Corp OH now owns 1,473 shares of the company’s stock worth $1,355,000 after acquiring an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare’s inclusion of GLP-1 weight-loss drugs has sparked renewed optimism that Eli Lilly’s obesity portfolio could reach more patients and drive additional sales. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Several market notes remain constructive on LLY, citing leadership in GLP-1 therapies, a broadening pipeline, and diversified growth drivers as support for long-term upside despite a rich valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Analysts and commentators highlighted Lilly as a top healthcare name, with some arguing the stock still has double-digit upside if GLP-1 demand and new products continue to scale. Eli Lilly Price Prediction: The Case for Double-Digit Upside
• Positive Sentiment: Lilly and Innovent reached a commercialization deal for Verzenios in China, which could expand access in oncology while preserving Lilly’s manufacturing role. Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
• Positive Sentiment: TipRanks said AI could become a meaningful long-term growth tailwind for Eli Lilly by improving drug discovery and development efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Neutral Sentiment: Lilly continued to receive favorable media coverage and mentions in broader pharma/medical stock screens, which may support investor attention but does not change fundamentals on its own.
• Negative Sentiment: U.S. lawmakers opened a national security probe into Lilly’s clinical trial activities in China, asking for details on oversight and data access by a July 17 deadline. Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers
• Negative Sentiment: China’s Hybio filed a patent challenge against Lilly’s tirzepatide, raising a potential intellectual-property risk for one of its most important weight-loss drugs. China’s Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide

Wall Street Analyst Weigh In

Several research firms have recently commented on LLY. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, June 22nd. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,235.07.

Eli Lilly and Company Stock Up 1.4%

Shares of LLY stock opened at $1,208.37 on Friday. The company has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 42.93, a PEG ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,238.00. The company’s fifty day moving average price is $1,059.70 and its 200-day moving average price is $1,026.87. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.